References
- AltmanDGMachinDBryantTNStatistics with Confidence2000BristolBMJ Bks
- BombardierCLaineLReicinAComparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study GroupN Engl J Med20003431520811087881
- CaulinCFrom the chemical product to the authorization of drug marketingRev Prat2002524869011949499
- HrachavecJBMoraMReporting of 6-month vs 12-month data in a clinical trial of celecoxib. Author replyJAMA20012862399400
- LaporteJRIbanezLVidalXUpper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agentsDrug Saf2004274112015144234
- LaytonDHeeleyEHuguesKComparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring dataRheumatology2003426223112709537
- MacDonaldTMMorantSVGoldsteinJLChannelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugsGut20035212657012912856
- MalhotraSPandhiPShafiqNCOX-2 inhibitors: a CLASS act or Just VIGORously promotedMedGenMed20046615208519
- Merck & Co.Merck anuncia la retirada voluntaria de la venta de VIOXX® en todo el mundo [online]2004 Accessed on 3 October 2004. URL: http://www.vioxx.com/vioxx/documents/spanish/vioxx_press_release.pdf
- MorideYDucruetTBoivinJFPrescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control studyArthritis Res Ther20057R3334215743481
- MukherjeeDNissenSETopolEJRisk of cardiovascular events associated with selective COX-2 inhibitorsJAMA2001286954911509060
- OfmanJJBadamgarayEHenningJMUtilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysisAm J Med20041168354215178499
- OkieSRaising the safety bar – the FDA’s coxib meetingN Eng J Med200535213
- PedrosCCereczaGLaporteJRPrimeras notificaciones espontáneas de sospechas de reacciones adversas a los nuevos anti-inflamatorios selectivos sobre la ciclooxigenasa-2Med Clin200211841517
- PelosoPMStrategies and practice for use of nonsteroidal antiinflammatory drugsScand J Rheumatol1996105Suppl2943
- RawsonNSNourjahPGrosserSCFactors associated with celecoxib and rofecoxib utilizationAnn Pharmacother20053959760215755796
- SahaiHKhurshidAStatistics in epidemiology. methods, techniques and applications1996Boca RatonCRC Pr
- SeibertKMasferrerJZhangYMediation of inflammation by cyclooxygenase-2Agents Actions199546Suppl4150
- SilversteinFEFaichGGoldsteinJLGastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety StudyJAMA200028412475510979111
- SimonLSActions and toxicity of nonsteroidal anti-inflammatory drugsCurr Opin Rheumatol19957159667612406
- SinghGRosen RameyDRNSAID reduced gastrointestinal complications: the ARAMIS perspective – 1997. Arthritis, Rheumatism and Aging Medical Information SystemJ Rheumatol199851Suppl816
- TramerMRMooreRAReynoldsDJQuantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID usePain2000851698210692616
- [UK MCA] Medicines and Healthcare products Regulatory AgencyMonitoring the safety and quality of medicines: Pharmacovigilance [online]2004 Accessed on 11 August 2004. URL: http://www.mhra.gov.uk
- VaneJRBottingRMMechanism of action of nonsteroidal antiinflammatory drugsAm J Med19981042S8S9572314
- VaneJRInhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugsNature19712312325
- [WHO] Norwegian Institute of Public HealthWorld Health Organisation Collaborating Centre for Drug Statistics Methodology [online]2004 Accessed on 3 October 2004. URL: http://www.whocc.no/atcddd
- WolfeFAndersonJBurkeTAGastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapyJ Rheumatol2002294677311908558
- WolfeFFlowersNBurkeTAIncrease in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritisJ Rheumatol20022910152212022317
- WolfeMMLichtensteinDRSinghGGastrointestinal toxicity of nonsteroidal anti-inflammatory drugsN Engl J Med199934018889910369853
- WrightJMPerryTLBassettKLReporting of 6-month vs 12-month data in a clinical trial of celecoxibJAMA2001286239840011712925
- ZhaoSZBurkeTAWheltonAComparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practiceAm J Manag Care2002815 SupplS39240012416789